ADVERUM BIOTECHNOLOGIES INC (ADVM)

US00773U2078 - Common Stock

9.53  +0.34 (+3.7%)

After market: 9.53 0 (0%)

Fundamental Rating

3

ADVM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ADVM as it has an excellent financial health rating, but there are worries on the profitability. ADVM is valied quite expensively at the moment, while it does show a decent growth rate.



0

1. Profitability

1.1 Basic Checks

In the past year ADVM has reported negative net income.
ADVM had a negative operating cash flow in the past year.
ADVM had negative earnings in each of the past 5 years.
In the past 5 years ADVM always reported negative operating cash flow.

1.2 Ratios

ADVM's Return On Assets of -67.73% is on the low side compared to the rest of the industry. ADVM is outperformed by 63.31% of its industry peers.
ADVM's Return On Equity of -140.38% is on the low side compared to the rest of the industry. ADVM is outperformed by 63.48% of its industry peers.
Industry RankSector Rank
ROA -67.73%
ROE -140.38%
ROIC N/A
ROA(3y)-50.31%
ROA(5y)-40.85%
ROE(3y)-90.51%
ROE(5y)-67.09%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ADVM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

7

2. Health

2.1 Basic Checks

ADVM does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADVM has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, ADVM has less shares outstanding
ADVM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ADVM has an Altman-Z score of -7.97. This is a bad value and indicates that ADVM is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ADVM (-7.97) is worse than 73.55% of its industry peers.
There is no outstanding debt for ADVM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.97
ROIC/WACCN/A
WACC9.31%

2.3 Liquidity

ADVM has a Current Ratio of 4.13. This indicates that ADVM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.13, ADVM is in line with its industry, outperforming 46.76% of the companies in the same industry.
A Quick Ratio of 4.13 indicates that ADVM has no problem at all paying its short term obligations.
With a Quick ratio value of 4.13, ADVM perfoms like the industry average, outperforming 47.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.13
Quick Ratio 4.13

5

3. Growth

3.1 Past

ADVM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -480.00%.
The Revenue has been growing by 17.46% on average over the past years. This is quite good.
EPS 1Y (TTM)-480%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-596.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y17.46%
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 14.02% on average over the next years. This is quite good.
Based on estimates for the next years, ADVM will show a very strong growth in Revenue. The Revenue will grow by 43.10% on average per year.
EPS Next Y38.66%
EPS Next 2Y17.66%
EPS Next 3Y13.02%
EPS Next 5Y14.02%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y43.1%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADVM. In the last year negative earnings were reported.
Also next year ADVM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ADVM's earnings are expected to grow with 13.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.66%
EPS Next 3Y13.02%

0

5. Dividend

5.1 Amount

No dividends for ADVM!.
Industry RankSector Rank
Dividend Yield N/A

ADVERUM BIOTECHNOLOGIES INC

NASDAQ:ADVM (4/29/2024, 7:00:00 PM)

After market: 9.53 0 (0%)

9.53

+0.34 (+3.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap197.75M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -67.73%
ROE -140.38%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.13
Quick Ratio 4.13
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-480%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y38.66%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y